21. Outcome of Weekly Carboplatin–Paclitaxel-based Definitive Chemoradiation in Oesophageal Cancer in Patients Not Considered to be Suitable for Platinum–Fluoropyrimidine-based Treatment: A Multicentre, Retrospective Review. Issue 2 (February 2020) Authors: Owens, R.; Cox, C.; Gomberg, S.; Pan, S.; Radhakrishna, G.; Parikh, S.; Goody, R.; Hingorani, M.; Prince, S.; Bird, T.; Dorey, N.; Macgregor, U.; Al-Chamali, H.; Hurt, C.; Mukherjee, S. Journal: Clinical oncology Issue: Volume 32:Issue 2(2020) Page Start: 121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
22. PD-0078 Three-year update of outcomes for SABR-treated extracranial oligometastases: A real world experience. (May 2022) Authors: Abutaleb, M.K.; Croxford, W.; Fatimilehin, A.; Bowen-Jones, S.; Bewley, M.; Colaco, R.; Hall, R.; Whitehurst, P.; Wooder, R.; Radhakrishna, G.; Woolf, D. Journal: Radiotherapy and oncology Issue: Volume 170(2022)Supplement 1 Page Start: S55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
23. PO-0713: Conformity analysis of target-volume definition for margin-directed boost in pancreatic cancer SBRT. (April 2016) Authors: Holyoake, D.; Robinson, M.; Grose, D.; Mcintosh, D.; Sebag-Montefiore, D.; Radhakrishna, G.; Patel, N.; Mukherjee, S.; Hawkins, M. Journal: Radiotherapy and oncology Issue: Volume 119(2016)Supplement 1 Page Start: S333 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
24. PO-0760: SCOPE trial involvement as driver of oesophageal radiotherapy developments in UK centres. (April 2018) Authors: Gwynne, S.; Higgins, E.; Poon King, A.; Radhakrishna, G.; Jones, G.; Wills, L.; Crosby, T. Journal: Radiotherapy and oncology Issue: Volume 127(2018)Supplement 1 Page Start: S392 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
25. PO-0769: NeoSCOPE RTTQA: pre-accrual and on-trial review of all patients in a UK oesophageal RT trial. (April 2018) Authors: Evans, E.; Jones, G.; Rackley, T.; Maggs, R.; Radhakrishna, G.; Mukherjee, S.; Hawkins, M.; Crosby, T.; Gwynne, S. Journal: Radiotherapy and oncology Issue: Volume 127(2018)Supplement 1 Page Start: S397 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
26. PO-0786: Outcomes from hypofractionated radiotherapy comparable to chemoradiotherapy in oesophageal cancer. (April 2018) Authors: Jones, C.; Spencer, K.; Hitchen, C.; Pelly, T.; Wood, B.; Hatfield, P.; Crellin, A.; Sebag-Montefiore, D.; Goody, R.; Crosby, T.; Radhakrishna, G. Journal: Radiotherapy and oncology Issue: Volume 127(2018)Supplement 1 Page Start: S406 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
27. PO-0810 Outcome following definitive radiotherapy in oesophageal cancer: A single UK centre experience. (April 2019) Authors: Mehta, S.; Mcpartlin, A.; Hodgson, C.; Radhakrishna, G.; Bhatt, L.; Sheikh, H. Journal: Radiotherapy and oncology Issue: Volume 133(2019)Supplement 1 Page Start: S422 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
28. PO-1037: A new nodal delineation protocol for upper third oesophageal cancers in the SCOPE 2 trial. (November 2020) Authors: Nicholas, O.; Radhakrishna, G.; Banner, R.; Mukherjee, S.; Hawkins, M.; Crosby, T.; Gwynne, S.H. Journal: Radiotherapy and oncology Issue: Volume 152(2020)Supplement 1 Page Start: S552 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
29. PO-1080: 4DCT oesophageal tumour delineation in SCOPE2 – how is radiotherapy quality assurance beneficial?. (April 2018) Authors: Cox, S.; Jones, G.; Radhakrishna, G.; Mukherjee, S.; Hawkins, M.; Crosby, T.; Gwynne, S. Journal: Radiotherapy and oncology Issue: Volume 127(2018)Supplement 1 Page Start: S608 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
30. PO-1286 Skeletal muscle measured at T12 is a prognostic biomarker in oesophageal cancer patients. (May 2022) Authors: McSweeney, D.; Radhakrishna, G.; Green, A.; Bromiley, P.A.; van Herk, M.; McWilliam, A. Journal: Radiotherapy and oncology Issue: Volume 170(2022)Supplement 1 Page Start: S1084 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗